what is glp-1 drugs Drugs: Fighting Diabetes and Weight Gain💊 - General Evolution of GLP‐1 Receptor Agonists

Recent studies have shown that circulating DPP-4 plays a role in obesity and cardiovascular diseases, and may represent an important molecular link between obesity, diabetes, and cardiovascular disease (Rhrborn et al., 2015)

9 GLP-1RAs should not be prescribed in patients with a history of pancreatitis, a personal or family history of medullary thyroid cancer, or multiple endocrine neoplasia due to the observed development of thyroid tumors in animal studies

however, several challenges still remain, especially the higher cost of a combined therapy and the worldwide underuse of either GLP-1RAs or SGLT2is in clinical practice, even in patients at high cardiorenal risk

The authors propose that a high CV risk be defined as patients with T2D duration of 10 years with at least one of the following: established CVD

Lillys Orforglipron Demonstrates Significant Weight Loss in Phase 2 Study